Redeye provides its comment on Mendus’ Q1 2025 report. CADENCE recently enrolled its first patient, while Mendus continues to focus on becoming phase III-ready with vididencel in AML in H2 2025e, which we believe will lead to business development opportunities. We update our estimates and valuation.
LÄS MER
